Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
about
Molecular biology of lung cancer: clinical implicationsThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPThe steady progress of targeted therapies, promising advances for lung cancerLung cancer chemoprevention: current status and future prospectsAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerHereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutationsNovel insights into the molecular origins and treatment of lung cancerAnalysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary reportMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsImage-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsCombined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.SHP2E76K mutant promotes lung tumorigenesis in transgenic miceTwist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.Alveolar type II cells possess the capability of initiating lung tumor developmentInhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneGermline EGFR T790M mutation found in multiple members of a familial cohort.Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.Heat shock protein 90 inhibition in lung cancer.Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone.Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung CancerTemporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaHow genetically engineered mouse tumor models provide insights into human cancersJAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitorsConcurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.Non-small cell lung cancer: the era of targeted therapy.Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
P2860
Q24610335-494B58B3-44B2-43A0-819B-5C489EB43C4BQ24649549-49935148-4023-46BD-BF1A-A4D064C933DBQ26746895-E08D0A8B-AABA-4514-9CD3-C5C5C18A4DA6Q26995495-E1794AB9-7BCF-4743-8693-0AE52E284C9CQ27853013-BC443ADA-89D4-4084-B071-2A00B9AC1E17Q28384015-4B03E6A7-3C7D-414B-ABAC-1D0382C19264Q28386773-7756C66F-C7A3-444C-96C3-D703BEE2AF0CQ28393099-42801FE2-7358-4563-BD52-111171D399D2Q30502341-906ED8CA-13C0-41CA-B381-5121D5F91B39Q30610005-EA26DAB7-EDEF-46DA-A5D5-59588D2052DDQ33332189-18D07002-75FB-41C9-8940-5A6C1A5CF4D7Q33757287-798F0373-7603-4CD7-B687-38206C37B386Q33819404-706DFAD6-4300-4136-93B0-2E74BB0B100BQ33897308-1F4D0BEF-6248-427F-89D0-78EE2EB0CEE2Q33901617-EA0C63F8-FEE5-47CC-8E21-BE5118832709Q33948614-EC427B21-D5FD-4F52-A5E5-3C71509CBAAAQ34009953-CCA5634F-C467-41F9-A24B-F263DFB60C24Q34288798-A5027638-A0DD-4F3C-84E9-89548939E380Q34535276-1018244C-02F8-4E27-AC13-9E3352F77758Q34593929-C4E4CCC9-48CD-4B75-86FC-0FCC8FA80234Q35546231-B9833B4E-F448-471E-9AE0-DA4C13DC1587Q35742500-28C02046-83FE-4D84-8D93-DF736D3DA419Q35762499-5BEB14DA-245E-45DF-AE5C-0EE47B9F64A6Q35793804-3667C2EC-F024-4AAE-A8BB-941784DB42C3Q36100853-5308A28A-CDB8-4AB6-AC28-A6AA237AD383Q36279031-F390A808-1F64-4633-9D58-F74CDDBF9BFFQ36407251-E7F14570-F588-466E-B198-75B657BA4810Q36951261-42A7CC45-CDFB-41AD-AE13-B5EEDA17595BQ37000611-30D26351-8F50-4BAF-B2EA-374E97D29353Q37065678-68DBED4E-0C87-43BD-9ED1-AA1F36A69173Q37107598-F4C6792E-FD76-4E42-ACA7-577C3E44B3C6Q37212135-250E432A-8F95-4B52-A928-17057CF7154DQ37277324-BD9ABD78-50BB-4DCD-9DB5-A07AD9FA8B61Q37363050-0472A4E3-5654-4DA1-8A2D-3F759E8E59B3Q37376100-25ED161C-A4F6-43B5-8FCB-25CBCBCC1283Q37417712-86588F39-7C09-4E97-B751-57A27C231E63Q37429049-25DA55E3-FE34-4C74-8017-1A661FFC1BCCQ37565381-7AA550B0-5331-408B-B6C1-A0D6A0E0A53FQ37645231-BA8F1A35-7253-4C9C-96AB-E5CD62152FEBQ37899883-A6B5D6E5-5267-49E0-A4E6-B7818EA6A7A2
P2860
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Development of new mouse lung ...... esistance to kinase inhibitors
@ast
Development of new mouse lung ...... esistance to kinase inhibitors
@en
Development of new mouse lung ...... esistance to kinase inhibitors
@nl
type
label
Development of new mouse lung ...... esistance to kinase inhibitors
@ast
Development of new mouse lung ...... esistance to kinase inhibitors
@en
Development of new mouse lung ...... esistance to kinase inhibitors
@nl
prefLabel
Development of new mouse lung ...... esistance to kinase inhibitors
@ast
Development of new mouse lung ...... esistance to kinase inhibitors
@en
Development of new mouse lung ...... esistance to kinase inhibitors
@nl
P2093
P2860
P3181
P1433
P1476
Development of new mouse lung ...... esistance to kinase inhibitors
@en
P2093
Ayana Sawai
David B Solit
Jason A Koutcher
Lucia Regales
Marissa N Balak
Maureen F Zakowski
Neal Rosen
Yixuan Gong
P2860
P3181
P356
10.1371/JOURNAL.PONE.0000810
P407
P577
2007-01-01T00:00:00Z